Vanguard Capital Management reported beneficial ownership of 10,113,219 shares of BioMarin Pharmaceutical Inc. Common Stock as of 03/31/2026, representing 5.25% of the class. The filing shows sole dispositive power over 10,113,219 shares and sole voting power over 1,470,055 shares.
The filing is a Schedule 13G disclosure listing passive/beneficial ownership by an investment manager and affiliated business divisions. The signature block is dated 04/29/2026 and is signed by Ashley Grim, Head of Global Fund Administration.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics. This French FDI clearance satisfies the final outstanding regulatory condition under the Merger Agreement, aside from items to be completed at closing.
The merger, in which Amicus will become a wholly owned subsidiary of BioMarin, is expected to close on April 27, 2026. The companies caution that this timing and other expectations are forward-looking and subject to risks described in their SEC filings and the Amicus merger proxy.
BioMarin Pharmaceutical Inc. is asking stockholders to elect ten directors, ratify KPMG as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares reserved under the 2017 Equity Incentive Plan at its June 2, 2026 virtual annual meeting.
The proxy highlights 2025 revenue of $3.2 billion, up 13%, with VOXZOGO reaching $927 million. It describes an all-cash agreement to acquire Amicus Therapeutics for about $4.8 billion and the completed $270 million acquisition of Inozyme Pharma. The Board chair role will transition from Richard A. Meier to Ian T. Clark.
BioMarin Pharmaceutical Inc Schedule 13G/A (Amendment No. 12) updates The Vanguard Group's reporting following an internal realignment. The filing states amount beneficially owned: 0 and percent of class: 0%. The Vanguard Group explains certain subsidiaries will report separately in reliance on SEC Release No. 34-39538 dated January 12, 1998.
The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026.
BioMarin Pharmaceutical executive George Eric Davis, EVP and Chief Legal Officer, reported a routine share disposition related to taxes. On this date, 1,273 shares of common stock were withheld to cover tax obligations at $56.05 per share. After this tax-withholding transaction, he directly holds 78,560 shares of BioMarin common stock, indicating he retains a substantial equity position and that the filing reflects a compensation-related event rather than an open-market sale.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer reported a tax-related share disposition. On the transaction date, 1,693 shares of common stock were withheld at a price of $56.05 per share to cover tax obligations, a non‑market transaction. After this event, he directly held 84,140 common shares.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported a tax-related share disposition. On March 17, 2026, 2,117 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly holds 123,314 common shares, indicating a routine, non–market sale event.
BioMarin Pharmaceutical Chief Executive Officer Alexander Hardy reported a routine share disposition related to taxes. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly held 214,635 shares.